http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
안명주 한양대학교 의과대학 2014 Hanyang Medical Reviews Vol.34 No.1
Lung cancer is the most common cause of cancer death worldwide. With advances in understanding of lung cancer biology and technology, there has been significant improvement in the treatment of non-small-cell lung cancer (NSCLC) during the last decades through the development of targeted agents for molecular subgroups harboring specific genomic abnormalities. So far, agents targeting Epidermal growth factor receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) have led to high and durable response rates in patients with EGFR mutation or ALK translocation. Also agents targeting VEGF improved overall survival even though a specific biomarker has not been defined yet. As more and more genomic alterations, such as ROS1, RET, MET, HER2, BRAF, FGFR1, DDR2, PI3KCA and K-ras, are being identified in NSCLC, new targeted agents for patients with specific genomic alterations have been developed and have showed promising results. Furthermore, promising results with immune checkpoint inhibitors such as CTLA4 inhibitors, PD-1 or PDL-1 antibody will shed light on further improvement of treatment of lung cancer in the near future. However, the evolving nature of cancer through the appearance of resistance to targeted agents and tumor heterogeneity would provide much challenge to conquer lung cancer. Unfortunately, since no significant progress has been achieved in targeted agents in small cell lung cancer, this review will focus on NSCLC and provides an overview of growing new targeted agents in the treatment of NSCLC.
진행성 대장암에 대한 5-Fluorouracil 및 Low Dose Leucovorin 복합화학 요법
안명주 ( An Myeong Ju ),서철원 ( Seo Cheol Won ),이규형 ( Lee Gyu Hyeong ),이정신 ( Lee Jeong Sin ),김상희 ( Kim Sang Hui ),김진천 ( Kim Jin Cheon ),박건춘 ( Park Geon Chun ) 대한내과학회 1992 대한내과학회지 Vol.42 No.6
연구배경 및 방법 : 1989년 11월부터 1991년 8월까지 울산의대 서울중앙병원 내과에 내원하여 전이성 또는 재발성 대장암 환자로 진단된 29예를 대상으로 5-fluor-ouracil 및 저용량 leucovorin 화학요법을 시행하여 다음과 같은 결과를 얻었다. 결과 : 1) 계측가능병변올 가진 27예의 환자중 완전반응은 2예(7%), 부분반응은 6예(22%)로 29%의 반응율을 보였고, 불변이 15예(56%), 진행이 4예(15%)였다. 2) 반응군의 반응유지기간의 중앙치는 30주였고, 비반응군에서는 10주였으며 두군 사이에는 통계학적으로 유의한 차이가 있었다. 전체 환자의 반응유지기간은 중앙치가 17주였으며 전체 환자의 생존기간의 중앙치는 30주였다. 3) 환자의 운동능력, 항암화학요법의 과거력, 원발병소, 전이장기 및 치료개시시의 CEA치에 따른 반응율의 비교에서는 통계학적 차이가 없었다. 4) 치료로 인한 부작용은 비교적 적게 나타났으며 그 정도도 경미하였다. 결론 : 이상의 결과로 5-fluorouracil 및 저용량 leu-covorin 화학요법이 전이성 또는 재발성 대장암환자의 치료에 있어서 비교적 부작용이 경미하면서도 중등도의 항암효과가 있다고 하겠다. Background A total of 29 patients with metastatic or recurrent colorectal carcinoma were studied to evaluate the effectiveness and toxicity of low dose leucovorin modulated 5-fluorouracil (5-FU). Methods: All patients were treated with low dose leucovorin, 20 ㎎/㎡ Ⅳ bolus on Days 1-5 and 5-fluorouracil, 400 ㎎/㎡ Ⅳ bolus on Days 1-5, every 4 weeks. Results: Of the 27 patients evaluable for response, 2(7%) had complete response and 6(22%) had partial response with the objective response rate of 29%. The median duration of response was 17 weeks and the median survival of all patients was 30 weeks. In the analysis of the response according to various characteristics of the patients, there was no significant difference (p> 0.05). Toxicity was mainly gastrointestinal, especially diarrhea and mucositis, but the grade was low. Hematologic toxicity was also mild. Conclusion: This study indicates that this regimen of low dose leucovorin plus 5-FU has mild toxicity, moderate response rate and good compliance for patients with recurrent and metastatic colorectal cancer.
안명주 한양대학교 의과대학 2002 한양의대 학술지 Vol.22 No.2
Umbilical cord blood (UCB) is another source of hematopoietic stem/progenitor cells (HSPC) including bone marrow and peripheral blood, and UCB is increasingly used for hematopoietic cell transplantation for the treatment of various genetic disease and hematologic disease/malignancies. Over the last ten years, many researches have focused on the purification, biological characterization, proliferation and expansion of UCB HPSC. Many studies have shown that HPSC from UCB is functionally different from that of bone marrow or peripheral blood, which has higher proliferation and expansion potential and contains more primitive progenitor cells. But, until now many unsolved problems about the biology of UCB stem cells remain. This review will describe and discuss briefly about the biology of UCB stem cells.